- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

- Data will highlight durability of treatment effect and significant impact on slowing disease progression. - No treatment-related serious adverse events (SAEs) or incidents of amyloid-related imaging ...

All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Learn more. New ...

Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...

Alzheimer's disease is a complicated and debilitating disease that has no cure. One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...

Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 million in a Series B funding round led by FoundersX Ventures, bringing its total ...